repotrectinib (Augtyro)

From Aaushi
Jump to navigation Jump to search

Indications

Dosage

  • 160 mg PO QD for 14 days
    • increase to 160 mg PO BID, with or without food.

Capsules: 40 mg

Adverse effects

Drug interactions

  • strong & moderate CYP3A inhibitors: avoid concurrent use
  • P-glucoprotein inhibitors: avoid concurrent use
  • strong & moderate CYP3A inducers: avoid concurrent use
  • hormonal contraceptives: avoid concurrent use

Mechanism of action

More general terms

References

  1. 1.0 1.1 Alexander Otto M FDA Expands Repotrectinib Label to All NTRK Gene Fusion+ Solid Tumors. Medscape. June 13, 2024 https://www.medscape.com/viewarticle/fda-expands-repotrectinib-label-all-ntrk-gene-fusion-solid-2024a1000b3q
  2. HIGHLIGHTS OF PRESCRIBING INFORMATION Augtyro <TM> (repotrectinib) capsules, for oral use https://packageinserts.bms.com/pi/pi_augtyro.pdf

Database